Progenika Biopharma, S.A.
Sergio Escorza. Director, International Strategic Alliances
Address: Parque Tecnológico de Bizkaia
City: 48160 Derio
Province: Bizkaia
Phone: 34 94 406 4525
Fax: 34 94 406 4526
Mission and Objectives
Progenika´s mission is to improve healthcare through the development, validation and commercialization of products that allow personalization of treatment for complex diseases: in vitro tests for their prevention, diagnosis and prognosis; prediction of response to drugs; and monitoring of the effectiveness of biologic therapies
Products/Services, Areas of interest for future collaborations/Alliances
Areas of expertise and interest for Progenika Group companies include:
Genotyping: Testing based on SNPs is applicable to a broad spectrum of studies, such as the identification of diseases and etiological research, gene association, mutational analyses, or associations between disease and gain/loss of chromosomal regions.
Massive sequencing: de novo and re-sequencing technologies allow gathering significant gene functional information, offering a high capacity and data quality unattainable by traditional sequencing.
Analyses of gene expression: our platforms make it possible to analyze simultaneously, in a quantitative and reproducible way, the expression levels of thousands of genes involved in a particular physiological process. Projects aimed at a restricted number of candidate genes and/or validation of expression markers is also possible.
Non-coding RNA: the large number of genes regulated by microRNAs makes the analysis of this kind of molecules particularly interesting to identify those that are associated with different pathologies.
Gene regulation: there are several technological options for the analysis of regulatory mechanisms, from massive sequencing studies applied to analysis of methylation to specific studies using microarrays.
Production of solid and liquid microarrays and immunoassays: tests for the detection of proteomic and genomic biomarkers can be implemented in different formats, such as ELISAs, chips, or liquid arrays based on suspended microspheres or microparticles.tion sequencing; or solid array, liquid array and immunoassay development

Progenika Biopharma, S.A.
Developed by Web4Bio